265 results on '"18F-Fluorocholine"'
Search Results
2. Diagnostic Performance of99m Tc-Sestamibi SPECT/CT and18 F-Choline PET/CT in Locating Hyperfunctioning Parathyroid Glands in Patients with Primary Hyperparathyroidism.
- Author
-
Mandic, Ante, Kraljevic, Ivana, Skoric Polovina, Tanja, Zibar Tomsic, Karin, Dusek, Tina, Balasko, Annemarie, Solak, Mirsala, and Kastelan, Darko
- Subjects
- *
PARATHYROID glands , *HYPERPARATHYROIDISM , *SINGLE-photon emission computed tomography , *PROTON magnetic resonance spectroscopy , *POSITRON emission tomography - Abstract
Objective This study aimed to assess the diagnostic performance of99m Tc-sestamibi SPECT/CT and18 F-choline PET/CT in detecting hyperfunctioning parathyroid glands in patients undergoing surgery for primary hyperparathyroidism (PHPT). Methods A retrospective analysis was conducted on patients who underwent PHPT-related surgery between April 2019 and May 2022. The study focused on patients undergoing either99m Tc-sestamibi SPECT/CT (81 patients) or18 F-choline PET/CT (33 patients) scans before surgery to pinpoint hyperfunctioning parathyroid gland(s). In the majority of patients,18 F-choline PET/CT was performed after negative or inconclusive findings on99m Tc-sestamibi SPECT/CT. Pathohistological reports were utilized as the reference standard for evaluating the accuracy of the imaging findings. Results The study encompassed 83 patients (70 females, 84.3%) with an average age of 57.2 years (24–80 years). The pathohistological analysis identified a total of 98 glands. In a per-lesion analysis, the detection rate of99m Tc-sestamibi SPECT/CT was 57% (95% CI 45.3–68.1), while the detection rate of18 F-choline PET/CT was 90.3% (95% CI 74.3–98.0). Conclusion The results of our study showed the significant usefulness of18 F-choline PET/CT in patients with negative or inconclusive results of99m Tc-sestamibi SPECT/CT in accurately locating hyperfunctioning parathyroid glands in PHPT patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Role of 18Fluorocholine Positron Emission Tomography/Computed Tomography in the Localization of Culprit Lesions in Patients of Persistent/Recurrent Primary Hyperparathyroidism: A Prospective Study in COVID Times.
- Author
-
Dharmashaktu, Ritwik Wakankar Yamini, Damle, A. Nishikant, Kumar, Praveen, Bal, Chandrasekhar, Kumar, Rakesh, Tripathi, Madhavi, Agarwal, Shipra, Khadgawat, Rajesh, Chumber, Sunil, and Kumar, Chitresh
- Subjects
- *
POSITRON emission tomography , *COMPUTED tomography , *HYPERPARATHYROIDISM , *COVID-19 , *LONGITUDINAL method , *RADIONUCLIDE imaging - Abstract
Introduction: Recurrent/persistent primary hyperparathyroidism in patients who have undergone previous parathyroidectomy is a challenging condition. Imaging is important for localizing the parathyroid adenoma for re-exploration and 18F-Fluorocholine (18F-FCH) positron emission tomography/computed tomography (PET/CT) seems ideal for this purpose. Aim: This prospective study attempted to ascertain the utility of 18F-FCH PET/CT as an investigation in preoperative localization of abnormal parathyroid tissue in recurrent/persistent primary hyperparathyroidism while comparing it with 99mTc-Sestamibi dual-phase scintigraphy with early single-photon emission CT (SPECT)/CT and neck ultrasonography (USG). Methods: Twenty patients with biochemical features of recurrent/persistent primary hyperparathyroidism were enrolled into this study. They underwent neck USG, 99mTc-Sestamibi dual-phase scintigraphy with early SPECT/CT and 18F-FCH PET/CT for localization of parathyroid lesions. Six patients underwent surgical resection of the detected lesions, 3 were awaiting surgery, and 11 were managed conservatively. One patient died due to COVID. Results: The calculated positive predictive values on a per-lesion basis of neck USG, 99mTc-sestamibi scintigraphy and early SPECT/CT and 18F-FCH PET/CT in the cohort of the 5 operated patients were 75% (3/4), 71.4% (5/7), and 71.4% (5/7), respectively. On a per-patient basis, the lesion detection rate was 100% for 99mTc-sestamibi scan and FCH PET (5/5) and 80% on neck USG (4/5). Conclusion: 18F-FCH PET/CT is a highly accurate imaging modality for the detection of parathyroid lesions in patients with recurrent/persistent primary hyperparathyroidism. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Teaching Cases in Nuclear Oncology: Prostatic Cancer
- Author
-
Volterrani, Duccio, Viglialoro, Rita, Puccini, Giulia, Mazzarri, Sara, Guidoccio, Federica, Volterrani, Duccio, editor, Erba, Paola A., editor, Strauss, H. William, editor, Mariani, Giuliano, editor, and Larson, Steven M., editor
- Published
- 2022
- Full Text
- View/download PDF
5. Diagnostic Applications of Nuclear Medicine: Parathyroid Tumors
- Author
-
Guidoccio, Federica, Mazzarri, Sara, Depalo, Tommaso, Mazzeo, Salvatore, Mariani, Giuliano, Volterrani, Duccio, editor, Erba, Paola A., editor, Strauss, H. William, editor, Mariani, Giuliano, editor, and Larson, Steven M., editor
- Published
- 2022
- Full Text
- View/download PDF
6. The relationship between 18F-FCH uptake intensity and cell content in parathyroid lesions.
- Author
-
Araz, Mine, Soydal, Çiğdem, Sütçü, Gizem, Kıvrak, Hale, Sak, Serpil Dizbay, Kır, K. Metin, and Küçük, N. Özlem
- Subjects
- *
HYPOPARATHYROIDISM , *PARATHYROID glands , *COMPUTED tomography , *POSITRON emission tomography , *RADIONUCLIDE imaging , *CELL anatomy - Abstract
Purpose: To investigate the relationship between cell content and histopathological features of parathyroid lesions and 18F-FCH uptake intensity on PET/CT images. Methods: Patients with primary hyperparathyroidism (age > 18) who were referred to 18F-FCH PET/CT were involved. All patients underwent parathyroidectomy. Correlation of SUVmax with following factors were statistically analysed: serum PTH, Ca, P levels and histopathological parameters, total absolute amounts of chief cell, oxyphyllic cell and clear cell components calculated by the multiplication of the volume of the parathyroid lesion and the percentage of each type of cell content (called as Absolutechief, Absoluteoxyphyllic and Absoluteclear reflecting the total amount of each cell group). Results: A total of 34 samples from 34 patients (6M, 28F, mean age: 53.32 ± 15.15, min: 14, max: 84) who had a positive 18F-FCH PET/CT localizing at least one parathyroid lesion were involved. In the whole study group, SUVmax was found to be correlated with the greatest diameter and volume of the lesion and Absolutechief (p = 0.004, p = 0.002 and p = 0.035, respectively). In the subgroup analysis of 28 samples with longest diameter > 1 cm, the correlation between SUVmax and Absolutechief remained significant (p = 0.036) and correlation between SUVmax and volume and longest diameter became stronger (p = 0.011 and p > 0.001, respectively). No correlation was found between SUVmax and Absoluteoxyphyllic or Absoluteclear. Conclusions: There might be a relationship between 18F-FCH uptake intensity and chief cell content in patients with parathyroid adenoma. Further studies with larger patient groups would be beneficial to support the data. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. 18 F-Fluorocholine PET/CT Compared with Current Imaging Procedures for Preoperative Localization of Hyperfunctioning Parathyroids in Patients with Chronic Kidney Disease.
- Author
-
Aymard, Samuel, Leroy-Freschini, Benjamin, Kaseb, Ashjan, Marx, David, Helali, Mehdi, Averous, Gerlinde, Betz, Valérie, Riehm, Sophie, Vix, Michel, Perrin, Peggy, and Imperiale, Alessio
- Subjects
- *
CHRONIC kidney failure , *CHRONICALLY ill , *KIDNEY transplantation , *PARATHYROID glands , *RADIONUCLIDE imaging - Abstract
Hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) includes secondary (sHPT) and tertiary hyperparathyroidism (tHPT). Considering that the role of preoperative imaging in the clinical setting is controversial, in the present study we have retrospectively compared pre-surgical diagnostic performances of 18F-Fluorocholine (18F-FCH) PET/CT, cervical ultrasonography (US), parathyroid scintigraphy, and 4D-CT in a group of 30 patients with CKD and HPT (18/12 sHPT/tHPT), 21 CKD G5 including 18 in dialysis, and 9 kidney transplant recipients. All patients underwent 18F-FCH, and 22 had cervical US, 12 had parathyroid scintigraphy, and 11 had 4D-CT. Histopathology was the gold standard. Seventy-four parathyroids were removed: 65 hyperplasia, 6 adenomas, and 3 normal glands. In the whole population, in a per gland analysis, 18F-FCH PET/CT was significantly more sensitive and accurate (72%, 71%) than neck US (25%, 43%), parathyroid scintigraphy (35%, 47%), and 4D-CT (40%, 47%). The specificity of 18F-FCH PET/CT (69%) was lower than that of neck US (95%) and parathyroid scintigraphy (90%), without, however, achieving significance. 18F-FCH PET/CT was more accurate than all other diagnostic techniques when sHPT and tHPT patients were considered separately. 18F-FCH PET/CT sensitivity was significantly higher in tHPT (88%) than in sHPT (66%). Three ectopic hyperfunctioning glands (in three different patients) were all detected by 18F-FCH PET/CT, two by parathyroid scintigraphy, and none by cervical US and 4D-CT. Our study confirms that 18F-FCH PET/CT is an effective preoperative imaging option in patients with CKD and HPT. These findings may be of greater importance in patients with tHPT (who could benefit from minimally invasive parathyroidectomy) than in patients with sHPT, who often undergo bilateral cervicotomy. In these cases, preoperative 18F-FCH PET/CT may be helpful in locating ectopic glands and may guide the surgical choice for gland preservation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Hyperfunctioning Intrathyroidal Parathyroid: a Misleading Preoperative Diagnosis.
- Author
-
Carullo, Josefina, Bani, Jacob, Averous, Gerlinde, Helali, Mehdi, Heimburger, Celine, Vix, Michel, and Imperiale, Alessio
- Abstract
Hyperfunctioning parathyroid glands may be rarely located in the thyroidal parenchyma and not identified by imaging or during surgical procedures. We present three patients with primary hyperparathyroidism related to hyperfunctioning intrathyroidal parathyroid retrospectively selected among 732 cases from own Institutional parathyroid PET/CT registry from 2018 to 2022. Intrathyroidal parathyroids showed intense
18 F-fluorocholine uptake but a variable echographic pattern, inconstant99m Tc-MIBI uptake, and atypic iodine-contrast enhancement. Although rare, the possibility of an intrathyroidal parathyroid should be considered when no hyperfunctioning gland is found on preoperative imaging and thorough bilateral neck exploration. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
9. Parathyroid Imaging in Patients with Renal Hyperparathyroidism
- Author
-
Hindié, Elif, Ureña-Torres, Pablo A., Taïeb, David, Covic, Adrian, editor, Goldsmith, David, editor, and Ureña Torres, Pablo A., editor
- Published
- 2020
- Full Text
- View/download PDF
10. Digital PET for recurrent prostate cancer: how the technology help
- Author
-
Ricci, Maria, Carabellese, Bruno, Pietroniro, Devis, Grivet Fojaja, Maria Rosaria, De Vincentis, Giuseppe, and Cimini, Andrea
- Published
- 2023
- Full Text
- View/download PDF
11. 18F-Fluorocholine PET/CT Compared with Current Imaging Procedures for Preoperative Localization of Hyperfunctioning Parathyroids in Patients with Chronic Kidney Disease
- Author
-
Samuel Aymard, Benjamin Leroy-Freschini, Ashjan Kaseb, David Marx, Mehdi Helali, Gerlinde Averous, Valérie Betz, Sophie Riehm, Michel Vix, Peggy Perrin, and Alessio Imperiale
- Subjects
hyperparathyroidism ,secondary hyperparathyroidism ,tertiary hyperparathyroidism ,chronic kidney disease ,parathyroid ,18F-fluorocholine ,Medicine (General) ,R5-920 - Abstract
Hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) includes secondary (sHPT) and tertiary hyperparathyroidism (tHPT). Considering that the role of preoperative imaging in the clinical setting is controversial, in the present study we have retrospectively compared pre-surgical diagnostic performances of 18F-Fluorocholine (18F-FCH) PET/CT, cervical ultrasonography (US), parathyroid scintigraphy, and 4D-CT in a group of 30 patients with CKD and HPT (18/12 sHPT/tHPT), 21 CKD G5 including 18 in dialysis, and 9 kidney transplant recipients. All patients underwent 18F-FCH, and 22 had cervical US, 12 had parathyroid scintigraphy, and 11 had 4D-CT. Histopathology was the gold standard. Seventy-four parathyroids were removed: 65 hyperplasia, 6 adenomas, and 3 normal glands. In the whole population, in a per gland analysis, 18F-FCH PET/CT was significantly more sensitive and accurate (72%, 71%) than neck US (25%, 43%), parathyroid scintigraphy (35%, 47%), and 4D-CT (40%, 47%). The specificity of 18F-FCH PET/CT (69%) was lower than that of neck US (95%) and parathyroid scintigraphy (90%), without, however, achieving significance. 18F-FCH PET/CT was more accurate than all other diagnostic techniques when sHPT and tHPT patients were considered separately. 18F-FCH PET/CT sensitivity was significantly higher in tHPT (88%) than in sHPT (66%). Three ectopic hyperfunctioning glands (in three different patients) were all detected by 18F-FCH PET/CT, two by parathyroid scintigraphy, and none by cervical US and 4D-CT. Our study confirms that 18F-FCH PET/CT is an effective preoperative imaging option in patients with CKD and HPT. These findings may be of greater importance in patients with tHPT (who could benefit from minimally invasive parathyroidectomy) than in patients with sHPT, who often undergo bilateral cervicotomy. In these cases, preoperative 18F-FCH PET/CT may be helpful in locating ectopic glands and may guide the surgical choice for gland preservation.
- Published
- 2023
- Full Text
- View/download PDF
12. Feasibility of 18 F-Fluorocholine PET for Evaluating Skeletal Muscle Atrophy in a Starved Rat Model.
- Author
-
Park, Sun Mi, Kim, Jisu, Baek, Suji, Jeon, Joo-Yeong, Lee, Sang Ju, Kang, Seo Young, Yoo, Min Young, Yoon, Hai-Jeon, Kwon, Seung Hae, Lim, Kiwon, Oh, Seung Jun, Kim, Bom Sahn, Lee, Kang Pa, and Moon, Byung Seok
- Subjects
- *
MUSCULAR atrophy , *SKELETAL muscle , *POSITRON emission tomography , *ANIMAL disease models , *COMPUTED tomography - Abstract
Imaging techniques for diagnosing muscle atrophy and sarcopenia remain insufficient, although various advanced diagnostic methods have been established. We explored the feasibility of 18F-fluorocholine (18F-FCH) positron emission tomography/computed tomography (PET/CT) for evaluating skeletal muscle atrophy, as an imaging technique that tracks choline level changes in muscles. Cell uptake in L6 cells by 18F-FCH was performed in a complete medium containing serum (untreated group, UN) and a serum-free medium (starved group, ST). Small-animal-dedicated PET/CT imaging with 18F-FCH was examined in in-vivo models with rats that were starved for 2 days to cause muscle atrophy. After the hind limbs were dissected, starvation-induced in-vivo models were anatomically confirmed by reverse-transcription polymerase chain reaction to evaluate the expression levels of the atrophy markers muscle RING-finger protein-1 (MuRF-1) and atrogin-1. 18F-FCH uptake was lower in the starvation-induced cells than in the untreated group, and in-vivo PET uptake also revealed a similar tendency (the average standardized uptake value (SUVmean) = 0.26 ± 0.06 versus 0.37 ± 0.07, respectively). Furthermore, the expression levels of MuRF-1 and atrogin-1 mRNA were significantly increased in the starvation-induced muscle atrophy of rats compared to the untreated group. 18F-FCH PET/CT may be a promising tool for diagnosing skeletal muscle atrophy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Parathyroid PET
- Author
-
Lezaic, Luka, Grmek, Marko, and Siraj, Qaisar Hussain, editor
- Published
- 2019
- Full Text
- View/download PDF
14. Parathyroid Scintigraphy
- Author
-
Siraj, Qaisar Hussain, Sergieva, Sonya Borisova, Javaid, Amir, and Siraj, Qaisar Hussain, editor
- Published
- 2019
- Full Text
- View/download PDF
15. Use of PET tracers for parathyroid localization: a systematic review and meta-analysis.
- Author
-
Kluijfhout, Wouter P, Pasternak, Jesse D, Drake, Frederick Thurston, Beninato, Toni, Gosnell, Jessica E, Shen, Wen T, Duh, Quan-Yang, Allen, Isabel E, Vriens, Menno R, de Keizer, Bart, Pampaloni, Miguel H, and Suh, Insoo
- Subjects
Humans ,Carbon Radioisotopes ,Methionine ,Radiopharmaceuticals ,Positron-Emission Tomography ,Parathyroidectomy ,Hyperparathyroidism ,Primary ,11C-Methionine ,18F-Fluorocholine ,Minimal invasive parathyroidectomy ,PET/CT ,Primary hyperparathyroidism ,Clinical Research ,Biomedical Imaging ,Bioengineering ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Clinical Sciences ,Surgery - Abstract
PurposeThe great spatial and temporal resolution of positron emission tomography might provide the answer for patients with primary hyperparathyroidism (pHPT) and non-localized parathyroid glands. We performed a systematic review of the evidence regarding all investigated tracers.MethodsA study was considered eligible when the following criteria were met: (1) adults ≥17 years old with non-familial pHPT, (2) evaluation of at least one PET isotope, and (3) post-surgical and pathological diagnosis as the gold standard. Performance was expressed in sensitivity and PPV.ResultsTwenty-four papers were included subdivided by radiopharmaceutical: 14 studies investigated L-[11C]Methionine (11C-MET), one [11C]2-hydroxy-N,N,N-trimethylethanamium (11C-CH), six 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG), one 6-[18F] fluoro-L-DOPA (18F-DOPA), and three N-[(18F)Fluoromethyl]-2-hydroxy-N,N-dimethylethanaminium (18F-FCH). The 14 studies investigating MET included a total of 327 patients with 364 lesions. Sensitivity for the detection of a lesion in the correct quadrant had a pooled estimate of 69 % (95 % CI 60-78 %). Heterogeneity was overall high with I2 of 51 % (p = 0.01) for all 14 studies. Pooled PPV ranged from 91 to 100 % with a pooled estimate of 98 % (95 % CI 96-100 %). Of the other investigated tracers, 18-FCH seems the most promising with high diagnostic performance.ConclusionsThe results of our meta-analysis show that 11C-MET PET has an overall good sensitivity and PPV and may be considered a reliable second-line imaging modality to enable minimally invasive parathyroidectomy. Our literature review suggests that 18F-FCH PET may produce even greater accuracy and should be further investigated using both low-dose CT and MRI for anatomical correlation.
- Published
- 2016
16. COVID-19 Pneumonia was Incidentally Detected on 18F-Fluorocholine PET/CT in a Work-up for Prostate Cancer.
- Author
-
Sahel, Omar Ait, Benameur, Yassir, Nabih, Salah Oueriagli, and Doudouh, Abderrahim
- Subjects
- *
PROSTATE cancer , *COVID-19 , *LUTEINIZING hormone releasing hormone , *PNEUMONIA , *COVID-19 pandemic , *CANCER patients - Abstract
This is a presentation of the case of a patient who underwent 18F-fluorocholine positron emission/computed tomography to stage a prostate cancer with incidentally found bilateral pneumonia. A high prevalence of incidental pneumonia is very probable under the current circumstance of coronavirus disease-2019 (COVID-19) pandemic, and oncological patients are at increased risk of COVID-19 with poorer outcome. The lung inflammatory burden in the case of COVID-19 infection can be demonstrated by 18F-fluorocholine. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Parathyroid imaging with 18F-fluorocholine PET/CT as a first-line imaging modality in primary hyperparathyroidism: a retrospective cohort study
- Author
-
Wouter A. M. Broos, Maurits Wondergem, Remco J. J. Knol, and Friso M. van der Zant
- Subjects
18F-fluorocholine ,PET/CT ,Primary hyperparathyroidism ,Parathyroid adenoma ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Abstract Background 18F-fluorocholine (FCH) PET/CT is a promising technique for visualizing hyperfunctioning parathyroid glands in hyperparathyroidism. It is still under debate whether to use this technique as a first-line imaging modality or to use it when conventional techniques such as 99mTc-sestamibi scintigraphy or ultrasonography are inconclusive. This study evaluates FCH PET/CT as a first-line modality. Methods Patients with primary hyperparathyroidism, referred between June 2015 and December 2018 for FCH PET/CT as a first-line imaging method, were included in this study. Baseline characteristics, clinical data, scan results, and type of treatment were recorded. The rate of correct detection was calculated on a per patient-based and a per lesion-based analysis. The reference standard comprised histopathological results, intraoperative response to parathyroidectomy, and clinical follow-up. Results Two hundred and seventy-one patients were included, of which 139 patients underwent parathyroidectomy, 48 were treated with calcimimetics, and 84 patients received further follow-up without active treatment. In the surgically treated group, a single adenoma was suspected in 127 scans, double adenoma in three scans, and one scan showed evidence of three hyperfunctioning glands. In eight scans, no lesions were visualized. A total of 154 parathyroid glands were surgically removed. The rate of correct detection was calculated at 96% and 90%, on a per patient-based and per lesion-based analysis, respectively. Conclusion This retrospective study in a large cohort shows high detection rates of FCH PET/CT in primary hyperparathyroidism, which is in accordance to literature. The use of FCH PET/CT as a first-line imaging modality in preoperative planning of parathyroid surgery may therefore be a suitable choice.
- Published
- 2019
- Full Text
- View/download PDF
18. Diagnostic Applications of Nuclear Medicine: Parathyroid Tumors
- Author
-
Guidoccio, Federica, Mazzarri, Sara, Mazzeo, Salvatore, Mariani, Giuliano, Strauss, H. William, editor, Mariani, Giuliano, editor, Volterrani, Duccio, editor, and Larson, Steven M., editor
- Published
- 2017
- Full Text
- View/download PDF
19. Feasibility of 18F-Fluorocholine PET for Evaluating Skeletal Muscle Atrophy in a Starved Rat Model
- Author
-
Sun Mi Park, Jisu Kim, Suji Baek, Joo-Yeong Jeon, Sang Ju Lee, Seo Young Kang, Min Young Yoo, Hai-Jeon Yoon, Seung Hae Kwon, Kiwon Lim, Seung Jun Oh, Bom Sahn Kim, Kang Pa Lee, and Byung Seok Moon
- Subjects
skeletal muscle atrophy ,18F-Fluorocholine ,positron emission tomography ,MuRF-1 ,atrogin-1 ,Medicine (General) ,R5-920 - Abstract
Imaging techniques for diagnosing muscle atrophy and sarcopenia remain insufficient, although various advanced diagnostic methods have been established. We explored the feasibility of 18F-fluorocholine (18F-FCH) positron emission tomography/computed tomography (PET/CT) for evaluating skeletal muscle atrophy, as an imaging technique that tracks choline level changes in muscles. Cell uptake in L6 cells by 18F-FCH was performed in a complete medium containing serum (untreated group, UN) and a serum-free medium (starved group, ST). Small-animal-dedicated PET/CT imaging with 18F-FCH was examined in in-vivo models with rats that were starved for 2 days to cause muscle atrophy. After the hind limbs were dissected, starvation-induced in-vivo models were anatomically confirmed by reverse-transcription polymerase chain reaction to evaluate the expression levels of the atrophy markers muscle RING-finger protein-1 (MuRF-1) and atrogin-1. 18F-FCH uptake was lower in the starvation-induced cells than in the untreated group, and in-vivo PET uptake also revealed a similar tendency (the average standardized uptake value (SUVmean) = 0.26 ± 0.06 versus 0.37 ± 0.07, respectively). Furthermore, the expression levels of MuRF-1 and atrogin-1 mRNA were significantly increased in the starvation-induced muscle atrophy of rats compared to the untreated group. 18F-FCH PET/CT may be a promising tool for diagnosing skeletal muscle atrophy.
- Published
- 2022
- Full Text
- View/download PDF
20. 18F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases.
- Author
-
Grkovski, Milan, Kohutek, Zachary A., Schöder, Heiko, Brennan, Cameron W., Tabar, Viviane S., Gutin, Philip H., Zhang, Zhigang, Young, Robert J., Beattie, Bradley J., Zanzonico, Pat B., Huse, Jason T., Rosenblum, Marc K., Blasberg, Ronald G., Humm, John L., and Beal, Kathryn
- Subjects
- *
STEREOTACTIC radiosurgery , *BRAIN metastasis , *SURGICAL excision , *LOG-rank test , *TUMORS - Abstract
Purpose: Radiographic changes of brain metastases after stereotactic radiosurgery (SRS) can signify tumor recurrence and/or radiation necrosis (RN); however, standard imaging modalities cannot easily distinguish between these two entities. We investigated whether 18F-Fluorocholine uptake in surgical samples of the resected lesions correlates with pathologic evidence of recurrent tumor and PET imaging. Methods: About 14 patients previously treated with SRS that developed radiographic changes were included. All patients underwent a preoperative 40-min dynamic PET/CT concurrent with 392 ± 11 MBq bolus injection of 18F-Fluorocholine. 18F-Fluorocholine pharmacokinetics were evaluated by standardized uptake value (SUV), graphical analysis (Patlak plot; KiP) and an irreversible two-compartment model (K1, k2, k3, and Ki). 12 out of 14 patients were administered an additional 72 ± 14 MBq injection of 18F-Fluorocholine 95 ± 26 minutes prior to surgical resection. About 113 resected samples from 12 patients were blindly reviewed by a neuropathologist to assess the viable tumor and necrotic content, microvascular proliferation, reactive gliosis, and mono- and polymorphonuclear inflammatory infiltrates. Correlation between these metrics 18F-Fluorocholine SUV was investigated with a linear mixed model. Comparison of survival distributions of two groups of patients (population median split of PET SUVmax) was performed with the log-rank test. Results: Exactly 10 out of 12 patients for which surgical samples were acquired exhibited pathologic recurrence. Strong correlation was observed between SUVmax as measured from a surgically removed sample with highest uptake and by PET (Pearson's r = 0.66). Patients with 18F-Fluorocholine PET SUVmax > 6 experienced poor survival. Surgical samples with viable tumor had higher 18F-fluorocholine uptake (SUV) than those without tumor (4.5 ± 3.7 and 2.6 ± 3.0; p = 0.01). 18F-fluorocholine count data from surgical samples is driven not only by the percentage viable tumor but also by the degree of inflammation and reactive gliosis (p ≤ 0.02; multivariate regression). Conclusions: 18F-Fluorocholine accumulation is increased in viable tumor; however, inflammation and gliosis may also lead to elevated uptake. Higher 18F-Fluorocholine PET uptake portends worse prognosis. Kinetic analysis of dynamic 18F-Fluorocholine PET imaging supports the adequacy of the simpler static SUV metric. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Superior performance of 18F-fluorocholine digital PET/CT in the detection of parathyroid adenomas.
- Author
-
López-Mora, Diego Alfonso, Sizova, Marina, Estorch, Montserrat, Flotats, Albert, Camacho, Valle, Fernández, Alejandro, Abouzian, Safae, Fuentes-Ocampo, Francisco, Garcia, José Ignacio Pérez, Ballesteros, Ana Isabel Chico, Duch, Joan, Domènech, Anna, Duarte, Antonio Moral, and Carrió, Ignasi
- Subjects
- *
NUCLEAR medicine , *LYMPH nodes - Abstract
Objective: To compare detectability of hyperfunctioning parathyroid tissue (HPT) by digital and analog 18F-fluorocholine PET/CT in patients with primary hyperparathyroidism and negative/inconclusive 99mTc-MIBI scintigraphy-SPECT/CT. Materials and methods: Thirty-three patients with primary hyperparathyroidism and negative/inconclusive 99mTc-MIBI scintigraphy-SPECT/CT were prospectively included. All patients accepted to be scanned by digital and analog PET/CT in the same imaging session after a single injection of 18F-fluorocholine. Three nuclear medicine physicians evaluated the digital and analog PET/CT datasets to assess the detection rate of HPT. Maximum standard uptake values (SUVmax) of HPT and locoregional lymph nodes were measured in both systems. Results: HPT was detected in 30/33 patients by the digital system, whereas it was detected in 22/33 patients by the analog system (p < 0.01). Moreover, in 21 of these 33 patients, both systems detected one focal 18F-fluorocholine uptake, and in one patient the digital system detected two foci. Histopathology demonstrated HPT in 32 patients and it was inconclusive in one patient. The digital PET/CT detected HPT in 29 of the 32 patients, and the analog system in 22 of the 32 (p < 0.01). All HPT suspected lesions resected and detected only by the digital system (n = 8) were < 10 mm (7.5 ± 1.3 mm), while those detected by both systems (n = 22) were > 10 mm (13 ± 3.8 mm). SUVmax of HPT lesions was significantly higher than SUVmax of locoregional lymph node independently of the PET/CT system used (4.5 ± 1.9 vs. 2.9 ± 1.3, p < 0.0001). Conclusions: Digital PET/CT offers superior performance over analog system in patients with suspected HPT and previous negative/inconclusive imaging examinations, particularly in sub-centimeter lesions. SUVmax can help in the differentiation between HTP and locoregional lymph nodes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
22. Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy.
- Author
-
Wallace, Michael C., Sek, Kenny, Francis, Roslyn J., Samuelson, Shaun, Ferguson, John, Tibballs, Jonathan, Asad, Ali, Preen, David B., MacQuillan, Gerry, Garas, George, Adams, Leon A., and Jeffrey, Gary P.
- Subjects
- *
HEPATOCELLULAR carcinoma , *POSITRON emission tomography computed tomography , *PROGRESSION-free survival , *HEPATITIS C , *COMPUTED tomography , *RESEARCH , *LIVER tumors , *CHRONIC hepatitis C , *FATTY liver , *ANTHROPOMETRY , *ALCOHOLIC liver diseases , *RESEARCH methodology , *CIRRHOSIS of the liver , *PROGNOSIS , *CHEMOEMBOLIZATION , *EVALUATION research , *MEDICAL cooperation , *CHOLINE , *TUMOR classification , *COMPARATIVE studies , *RADIOPHARMACEUTICALS , *MULTIPLE tumors , *RADIOISOTOPE brachytherapy , *RADIOSURGERY , *ABLATION techniques , *DISEASE complications - Abstract
Background and Aims: 18F-fluorocholine positron emission tomography/computed tomography (18F-FCH PET/CT) is an emerging functional imaging technique in the diagnosis and management of hepatocellular carcinoma (HCC). The aim of this study was to assess the ability of a pre- and post-treatment 18F-FCH PET/CT to predict prognosis and treatment response in early-stage HCC.Methods: Patients with early- or intermediate-stage HCC planned for locoregional therapy were prospectively enrolled. Baseline demographic and tumor information was collected and baseline and post-treatment 18F-FCH PET/CT performed. Maximum standardized uptake values (SUVmax) were determined for each HCC lesion, and the difference between baseline and post-treatment SUVmax values were compared with progression-free survival outcomes.Results: A total of 29 patients with 39 confirmed HCC lesions were enrolled from a single clinical center. Patients were mostly men (89.7%) with hepatitis C or alcohol-related cirrhosis (65.5%) and early-stage disease (89.7%). Per-patient and per-lesion sensitivity of 18F-FCH PET/CT was 72.4% and 59.0%, respectively. A baseline SUVmax < 13 was associated with a superior median progression-free survival compared with an SUVmax of > 13 (17.7 vs. 5.1 months; p = 0.006). A > 45% decrease in SUVmax between baseline and post-treatment 18F-FCH PET/CT ("responders") was associated with a superior mean progression-free survival than a percentage decrease of < 45% ("non-responders," 36.1 vs. 11.6 months; p = 0.034).Conclusions: Baseline and post-treatment 18F-FCH PET/CT predicts outcomes in early-stage HCC undergoing locoregional therapy. This technique may identify patients with an objective response post-locoregional therapy who would benefit from further therapy. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
23. Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer.
- Author
-
Lépinoy, Alexis, Silva, Yannick E., Cochet, Alexandre, Martin, Etienne, Quivrin, Magali, Créhange, Gilles, Bertaut, Aurélie, and Aubignac, Léone
- Subjects
- *
RADIOTHERAPY , *PROSTATE cancer , *RADIOACTIVE tracers , *POSITRON emission , *LYMPH nodes - Abstract
Purpose: The concept of metastasis-directed therapy for nodal oligorecurrences with stereotactic body radiotherapy is increasingly accepted. Hence, the comparison between salvage extended field radiotherapy (s-EFRT) and salvage involved field radiotherapy (s-IFRT) in patients with 18F-fluorocholine (FCH) PET/CT+ nodal oligorecurrences from prostate cancer is worthy of investigation.Methods: Patients with oligorecurrent nodes on FCH PET/CT treated with salvage radiotherapy between 2009 and 2017 in a single tertiary cancer centre were selected for this study. Patients treated with s-IFRT were compared with those treated with s-EFRT. Toxicities and times to failure (TTF) were compared between the two groups.Results: The study included 62 patients with positive lymph nodes only who underwent FCH PET/CT for a rising PSA level after radical prostatectomy or radiotherapy. Of these patients, 35 had s-IFRT and 27 had s-EFRT. After a median follow-up of 41.8 months (range 5.9-108.1 months), no differences were observed in acute or late gastrointestinal and genitourinary toxicities of grade 2 or more between the two groups. The 3-year failure rates were 55.3% (95% CI 37.0-70.3%) in the s-IFRT group and 88.3% (95% CI 66.9-96.1%) in the s-EFRT group (p = 0.0094). In multivariate analysis of TTF, an interval of >5 years was significantly correlated with better outcomes (HR = 0.33, 95% CI 0.13-0.86, p = 0.023). There was a strong trend toward better outcomes with s-EFRT even after adjusting for concomitant androgen-deprivation therapy (HR = 0.38, 95% CI 0.12-1.27, p = 0.116).Conclusion: FCH PET-positive node-targeted s-EFRT is feasible with low rates of toxicity and longer TTF, suggesting that oligorecurrent nodal disease diagnosed on FCH PET is unlikely. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
24. Superior sensitivity of 18F-fluorocholine: PET localization in primary hyperparathyroidism
- Author
-
Claire E. Graves, Thomas A. Hope, Julie Ann Sosa, Carolyn D. Seib, Quan-Yang Duh, Jessica E. Gosnell, Insoo Suh, Miguel Hernandez Pampaloni, Wen T. Shen, Wouter P. Kluijfhout, Jina Kim, and Sanziana A. Roman
- Subjects
Parathyroidectomy ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Ultrasound ,Mediastinum ,Magnetic resonance imaging ,Gold standard (test) ,medicine.disease ,medicine.anatomical_structure ,Positron emission tomography ,medicine ,Surgery ,business ,Nuclear medicine ,18F-fluorocholine ,Primary hyperparathyroidism - Abstract
Background Preoperative parathyroid imaging guides surgeons during parathyroidectomy. This study evaluates the clinical impact of 18F-fluorocholine positron emission tomography for preoperative parathyroid localization on patients with primary hyperparathyroidism. Methods Patients with primary hyperparathyroidism and indications for parathyroidectomy had simultaneous 18F-fluorocholine positron emission tomography imaging/magnetic resonance imaging. In patients who underwent subsequent parathyroidectomy, cure was based on lab values at least 6 months after surgery. Location-based sensitivity and specificity of 18F-fluorocholine positron emission tomography imaging was assessed using 3 anatomic locations (left neck, right neck, and mediastinum), with surgery as the gold standard. Results In 101 patients, 18F-fluorocholine positron emission tomography localized at least 1 candidate lesion in 93% of patients overall and in 91% of patients with previously negative imaging, leading to a change in preoperative strategy in 60% of patients. Of 76 patients who underwent parathyroidectomy, 58 (77%) had laboratory data at least 6 months postoperatively, with 55/58 patients (95%) demonstrating cure. 18F-fluorocholine positron emission tomography successfully guided curative surgery in 48/58 (83%) patients, compared with 20/57 (35%) based on ultrasound and 13/55 (24%) based on sestamibi. In a location-based analysis, sensitivity of 18F-fluorocholine positron emission tomography (88.9%) outperformed both ultrasound (37.1%) and sestamibi (27.5%), as well as ultrasound and sestamibi combined (47.8%). Conclusion Long-term results in the first cohort in the United States to use 18F-fluorocholine positron emission tomography for parathyroid localization confirm its utility in a challenging cohort, with better sensitivity than ultrasound or sestamibi.
- Published
- 2022
- Full Text
- View/download PDF
25. 18F-Fluorocholine PET/CT, Tc-99m-MIBI and TC-99m-MDP SPECT/CT in Tertiary Hyperparathyroidism with Renal Osteodystrophy
- Author
-
Cristina Ferrari, Valentina Lavelli, Giulia Santo, Maria Teresa Frugis, Francesca Iuele, Giuseppe Rubini, and Angela Sardaro
- Subjects
tertiary hyperparathyroidism ,renal osteodystrophy ,dual-phase Tc-99m-MIBI ,18F-fluorocholine ,positron emission tomography/computed tomography ,Tc-99m-MDP ,Medicine (General) ,R5-920 - Abstract
Tertiary hyperparathyroidism (HPT) is a metabolic disorder characterized by the semi-autonomous hypersecretion of parathyroid hormone (PTH), leading to hypercalcemia. It can be the end result of persistent secondary hyperparathyroidism and is most commonly observed in patients with long-standing chronic kidney disease (CKD) and often after renal transplantation. Untreated HPT can lead to progressive bone disease, fibrocystic osteitis, and soft-tissue calcifications, along with other severe complications. In the 2009 Kidney Disease Improving Global Outcomes (KDIGO) guidelines, CKD-Mineral and Bone Disorder (CKD-MBD) is used to describe the broader clinical syndrome encompassing mineral, bone, and calcific cardiovascular abnormalities that develop as a complication of CKD. We report a 62-year-old female with a severe HPT evolved from advanced chronic kidney disease (stage 5D, KDIGO). Patient was evaluated with multimodality nuclear medicine functional imaging to assess hyperfunctioning parathyroid glands and bone lesions. Tc-99m-methoxyisobutylisonitrile (MIBI) dual-phase scintigraphy, Tc-99m-methylenediphosphonate (MDP) bone scan and 18F-Fluorocholine positron emission tomography/computed tomography (18F-FCH PET/CT) were performed before surgery.
- Published
- 2020
- Full Text
- View/download PDF
26. Dural Metastases of Advanced Prostate Cancer Detected by 18F-Fluorocholine
- Author
-
Mauro Morassi, Mattia Bonacina, Claudio Bnà, Alberto Zaniboni, and Giordano Savelli
- Subjects
18F-fluorocholine ,prostate cancer ,computed tomography ,dural metastases ,subdural hematomas ,Medicine (General) ,R5-920 - Abstract
Prostate cancer with extensive dural metastases is very rare, with only few cases described in the literature. We report one such case of a 74-year-old man with advanced prostate cancer, and in relatively good clinical condition. The patient returned with complaints of headache and diplopia. Fluorocholine (18F) chloride (18F-FCH) is an analog of choline in which a hydrogen atom has been replaced by fluorine (18F). After crossing the cell membrane by a carrier-mediated mechanism, choline is phosphorylated by choline kinase to produce phosphorylcholine. 18F-FCH positron emission tomography–computed tomography (PET/CT) is widely used to stage and restage patients affected by prostate cancer with good sensitivity. 18F-FCH PET/CT showed disease progression with the onset of multiple skull lesions. Numerous suspicious dural hypermetabolic lesions indicating neoplastic involvement were detected along the fronto-parietal convexities, in the left fronto-orbital region and right lateral wall of the orbit, concerning for metastases in these regions. A contrast-enhanced computed tomography (CECT) scan was performed which showed corresponding enhancing tissue which correlated with the PET findings. The final imaging diagnosis was osteo-dural metastases from prostate cancer associated with poor outcome. Awareness of this pattern of metastases may be of clinical relevance in order to avoid unnecessary invasive diagnostic procedures in groups of patients with a dismal prognosis.
- Published
- 2020
- Full Text
- View/download PDF
27. Fluorocholine PET Imaging of Parathyroid Disease.
- Author
-
Prabhu, Meghana and Damle, Nishikant A.
- Subjects
- *
PARATHYROID gland diseases , *THYROID gland radiography , *DIAGNOSIS - Abstract
To give an overview of the potential clinical utility of 18F-fluorocholine PET/CT (FCH PET/CT) in imaging of parathyroid adenoma. Available studies have provided preliminary results of 18F-FCH PET/CT in primary and secondary hyperparathyroidism. Results of various studies have shown that 18F-FCH is a promising upcoming tracer for the detection of parathyroid adenomas, especially when multiple, or having low size. FCH PET/CT has the potential to be a standard investigation in the detection of parathyroid lesions. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
28. Dual Pathologies of Parathyroid Adenoma and Papillary Thyroid Cancer on Fluorocholine and Fluorodeoxyglucose PET/CT.
- Author
-
Thanseer, N. T. K., Bhadada, Sanjay Kumar, Sood, Ashwani, Parihar, Ashwin Singh, Dahiya, Divya, Singh, Priyanka, Basher, Rajender Kumar, Das, Ashim, and Mittal, Bhagwant R.
- Abstract
18 F-Fluorocholine (FCH) PET/CT is evolving as a functional imaging modality for the preoperative imaging of abnormal parathyroid tissue(s) helping to localize eutopic and ectopic parathyroid tissue and limit the extent of surgery. FCH PET/CT may show incidental uptake in various thyroid lesions necessitating further evaluation, whereas the role of18 F-fluorodeoxyglucose (FDG) PET/CT in the detection of incidental thyroid nodules is well documented. The case of a middle-aged woman with dual pathology of parathyroid adenoma and papillary thyroid cancer detected on FCH and FDG PET/CT is presented. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
29. 18F-Fluorocholine Positron Emission Tomography/Computed Tomography is a Highly Sensitive but Poorly Specific Tool for Identifying Malignancy in Thyroid Nodules with Indeterminate Cytology: The Chocolate Study
- Author
-
Bénédicte Clarisse, Jean-Michel Grellard, Renaud Ciappuccini, Dominique De Raucourt, Idlir Licaj, D. Blanchard, Emmanuel Babin, Justine Lequesne, Damien Peyronnet, Vianney Bastit, Stéphane Bardet, Audrey Lasne-Cardon, and Virginie Saguet-Rysanek
- Subjects
Thyroid nodules ,medicine.medical_specialty ,PET/CT ,Endocrinology, Diabetes and Metabolism ,indeterminate cytology ,030209 endocrinology & metabolism ,Malignancy ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Cytology ,Medicine ,Positron Emission Tomography-Computed Tomography ,Thyroid Radiology and Nuclear Medicine ,PET-CT ,business.industry ,thyroid nodules ,fluorocholine PET/CT ,medicine.disease ,Highly sensitive ,030220 oncology & carcinogenesis ,Radiology ,18F-choline PET/CT ,Indeterminate ,business ,18F-fluorocholine - Abstract
Background: Refining the risk of malignancy in patients presenting with thyroid nodules with indeterminate cytology (IC) is a critical challenge. We investigated the performances of 18F-fluorocholine (FCH) positron emission tomography/computed tomography (PET/CT) to predict malignancy. Methods: Between May 2016 and March 2019, 107 patients presenting with a thyroid nodule ≥15 mm with IC and eligible for surgery were included in this prospective study. Head-and-neck PET/CT acquisitions were performed 20 and 60 minutes after injection of 1.5 MBq/kg of FCH. PET/CT acquisition was scored positive when maximal standardized uptake value in the IC nodule was higher than in the thyroid background. Pathology was the gold standard for diagnosis. Results: At pathology, 19 (18%) nodules were malignant, 87 were benign, and one was a noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Sensitivity, specificity, accuracy, positive-predictive value (PPV), and negative-predictive value (NPV) of FCH PET/CT in detecting cancer or NIFTP were 90%, 50%, 55%, 29%, and 96% at 20 minutes and 85%, 49%, 67%, 28%, and 94% at 60 minutes, respectively. Higher specificity (58% vs. 33%, p = 0.01) was observed in nononcocytic (n = 72) than in oncocytic IC nodules (n = 35). The pre-PET/CT probability of cancer or NIFTP in Bethesda III–IV nodules was 11% and the post-PET/CT probability was 19% in PET-positives and 0% in PET-negatives. In retrospective analysis, 42% of surgeries would have been unnecessary after PET/CT and 81% before (p
- Published
- 2021
- Full Text
- View/download PDF
30. Imaging HCC treated with radioembolization: review of the literature and clinical examples of choline PET utility
- Author
-
Castello, Angelo and Lopci, Egesta
- Published
- 2020
- Full Text
- View/download PDF
31. Accuracy of 18F-Fluorocholine PET for the Detection of Parathyroid Adenomas: Prospective Single-Center Study
- Author
-
Javier Villanueva-Meyer, Jessica E. Gosnell, Wen T. Shen, Julie Ann Sosa, Daniel Thompson, Geoffrey B. Johnson, Claire Graces, Quan-Yang Duh, Sanziana A. Roman, Wouter P. Kluijfhout, Jeremie Calais, Eric C. Ehman, Carolyn Seib, Insoo Suh, Miguel Hernandez Pampaloni, Maya Aslam, and Thomas A. Hope
- Subjects
Parathyroidectomy ,Hyperparathyroidism ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Single Center ,medicine.disease ,Positron emission tomography ,medicine ,Clinical endpoint ,Radiology, Nuclear Medicine and imaging ,Nuclear medicine ,business ,Prospective cohort study ,18F-fluorocholine ,Primary hyperparathyroidism - Abstract
Purpose: The purpose of this prospective study was to determine the correct localization rate (CLR) of 18F-fluorocholine (FCH) positron emission tomography (PET) for the detection of parathyroid adenomas in comparison to sestamibi imaging. Materials and Methods: This was a single-arm prospective trial. Ninety-eight patients with biochemical evidence of primary hyperparathyroidism were imaged prior to parathyroidectomy using FCH PET/MRI. Sestamibi imaging performed separately from the study was evaluated for comparison. The primary endpoint of the study was the CLR on a patient level. Each imaging study was interpreted by 3 blinded readers on a per-region basis. Lesions were validated by histopathologic analysis of surgical specimens. Results: Of the 98 patients who underwent FCH imaging, 77 subsequently underwent parathyroidectomy and 60 of those had sestamibi imaging. The CLR for FCH in patients who underwent parathyroidectomy based on the blinded reader consensus was 75% [0.63, 0.82]. In patients who underwent surgery and had an available sestamibi study, the CLR increased from 17% [0.10, 0.27] for sestamibi to 70% [0.59, 0.79] for FCH PET. Conclusion: In this prospective study using blinded readers, the CLR for FCH was 75%. In patients with paired sestamibi, the use of FCH PET increased the CLR from 17% to 70%. FCH PET is a superior imaging modality for the localization of parathyroid adenomas.
- Published
- 2021
- Full Text
- View/download PDF
32. Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis
- Author
-
Insoo Suh, Julia Whitman, Emily K. Bergsland, Isabel E. Allen, and Thomas A. Hope
- Subjects
Adult ,Technetium Tc 99m Sestamibi ,medicine.medical_specialty ,Adenoma ,Clinical Sciences ,99mTc-sestamibi ,030218 nuclear medicine & medical imaging ,hyperparathyroidism ,Parathyroid Glands ,03 medical and health sciences ,Endocrinology ,0302 clinical medicine ,Positron Emission Tomography Computed Tomography ,fluorocholine ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,In patient ,Aged ,Hyperparathyroidism ,Receiver operating characteristic ,business.industry ,Ultrasound ,Middle Aged ,medicine.disease ,99mTc Sestamibi ,Nuclear Medicine & Medical Imaging ,PET ,Parathyroid Neoplasms ,030220 oncology & carcinogenesis ,Meta-analysis ,adenoma ,Biomedical Imaging ,Radiology ,business ,18F-fluorocholine - Abstract
Hyperparathyroidism is an endocrine disorder caused by one or more hyperfunctioning parathyroid glands. Current imaging consisting of ultrasound and (99m)Tc-sestamibi is imprecise, making localization difficult. (18)F-fluorocholine ((18)F-FCH) PET has recently shown promise in presurgical localization of parathyroid adenomas. The primary aim of this study was to summarize the sensitivities and specificities of studies using (18)F-FCH PET to localize hyperparathyroidism. A secondary aim was to summarize a subset of studies in which (99m)Tc-sestamibi scans were also used and to compare the performance of the 2 modalities. Methods: We searched the MEDLINE and EMBASE databases following the PRISMA (Preferred Reporting Items for Systematic Review and Metaanalysis) statement. Quality was assessed using the QUADAS-2 tool (Quality Assessment of Diagnostic Accuracy Studies). Twenty studies were included for quantitative assessment in our metaanalysis. A random-effects model and a hierarchic summary receiver-operating-characteristic model was used to summarize the sensitivity of (18)F-FCH PET in detecting abnormal parathyroid adenomas. We used the same methodology to assess sensitivity of (99m)Tc-sestamibi, as a comparison to (18)F-FCH PET. Results: (18)F-FCH PET had a high sensitivity, 0.97 (range, 0.96–0.98), for the detection of abnormal parathyroid adenomas. In the subpopulation for which both (18)F-FCH and (99m)Tc-sestamibi were reported, (18)F-FCH also had a higher sensitivity, 0.96 (0.94–0.98), than the 0.54 (0.29–0.79) reported for (99m)Tc-sestamibi (P < 0.001). Conclusion: (18)F-FCH PET demonstrates high localization accuracy in patients with hyperparathyroidism. This metaanalysis supports the use of (18)F-FCH over (99m)Tc-sestamibi in patients with hyperparathyroidism.
- Published
- 2021
- Full Text
- View/download PDF
33. High turnover renal osteodystrophy due to secondary hyperparathyroidism diagnosed by 18F-Fluorocholine combined with 18F-NaF PET/CT
- Author
-
Lin Xiong, Liang Cai, Yue Chen, Santao Ou, and Weihua Wu
- Subjects
medicine.medical_specialty ,Letter ,medicine.medical_treatment ,030232 urology & nephrology ,Urology ,030204 cardiovascular system & hematology ,urologic and male genital diseases ,Critical Care and Intensive Care Medicine ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Renal osteodystrophy ,Letter to the Editor ,PET-CT ,business.industry ,Incidence (epidemiology) ,General Medicine ,medicine.disease ,Diseases of the genitourinary system. Urology ,Nephrology ,Secondary hyperparathyroidism ,Hemodialysis ,RC870-923 ,Complication ,business ,18F-fluorocholine ,Kidney disease - Abstract
Dear Editor,Renal osteodystrophy (ROD) is a common complication in patients with chronic kidney disease (CKD), especially in hemodialysis patients, which is closely related to the incidence of frac...
- Published
- 2021
34. Role of 18 Fluorocholine Positron Emission Tomography/Computed Tomography in the Localization of Culprit Lesions in Patients of Persistent/Recurrent Primary Hyperparathyroidism: A Prospective Study in COVID Times.
- Author
-
Wakankar R, Dharmashaktu Y, Damle AN, Kumar P, Bal C, Kumar R, Tripathi M, Agarwal S, Khadgawat R, Chumber S, and Kumar C
- Abstract
Introduction: Recurrent/persistent primary hyperparathyroidism in patients who have undergone previous parathyroidectomy is a challenging condition. Imaging is important for localizing the parathyroid adenoma for re-exploration and
18 F-Fluorocholine (18 F-FCH) positron emission tomography/computed tomography (PET/CT) seems ideal for this purpose., Aim: This prospective study attempted to ascertain the utility of18 F-FCH PET/CT as an investigation in preoperative localization of abnormal parathyroid tissue in recurrent/persistent primary hyperparathyroidism while comparing it with99m Tc-Sestamibi dual-phase scintigraphy with early single-photon emission CT (SPECT)/CT and neck ultrasonography (USG)., Methods: Twenty patients with biochemical features of recurrent/persistent primary hyperparathyroidism were enrolled into this study. They underwent neck USG,99m Tc-Sestamibi dual-phase scintigraphy with early SPECT/CT and18 F-FCH PET/CT for localization of parathyroid lesions. Six patients underwent surgical resection of the detected lesions, 3 were awaiting surgery, and 11 were managed conservatively. One patient died due to COVID., Results: The calculated positive predictive values on a per-lesion basis of neck USG,99m Tc-sestamibi scintigraphy and early SPECT/CT and18 F-FCH PET/CT in the cohort of the 5 operated patients were 75% (3/4), 71.4% (5/7), and 71.4% (5/7), respectively. On a per-patient basis, the lesion detection rate was 100% for99m Tc-sestamibi scan and FCH PET (5/5) and 80% on neck USG (4/5)., Conclusion:18 F-FCH PET/CT is a highly accurate imaging modality for the detection of parathyroid lesions in patients with recurrent/persistent primary hyperparathyroidism., Competing Interests: There are no conflicts of interest., (Copyright: © 2023 Indian Journal of Nuclear Medicine.)- Published
- 2023
- Full Text
- View/download PDF
35. Evaluation of recurrent parathyroid carcinoma: A new imaging tool in uncommon entity.
- Author
-
Thanseer, N. T. K., Parihar, Ashwin, Sood, Ashwani, Bhadada, Sanjay, Dahiya, Divya, Singh, Priyanka, and Mittal, Bhagwant
- Subjects
- *
POSITRON emission tomography , *COMPUTED tomography , *CARCINOMA , *DISEASE relapse - Abstract
Parathyroid carcinoma (PTC) is a rare endocrine tumor and uncommon cause for primary hyperparathyroidism.18F-fluorocholine (FCH) positron emission tomography and computed tomography (PET/CT) has shown promising results in the detection of parathyroid adenoma, though its role in PTC is undefined due to the paucity of incidence. The authors in this case report discuss the possible complimentary role of FCH PET/CT with18F-fluorodeoxyglucose PET/CT in the evaluation of the management of suspected recurrence, since this rare entity has high loco-regional and distant recurrence of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
36. Paget bone disease demonstrated on 18F-fluorocholine PET/CT: a case report
- Author
-
Antonino Mazzone, Antonella Laria, Katia Angela Re, Alfredomaria Lurati, Paola Faggioli, Daniela Mazzocchi, and Mariagrazia Marrazza
- Subjects
PET-CT ,medicine.medical_specialty ,Bone disease ,medicine.diagnostic_test ,business.industry ,Cancer ,medicine.disease ,Chronic disorders ,030218 nuclear medicine & medical imaging ,Bone remodeling ,03 medical and health sciences ,0302 clinical medicine ,Positron emission tomography ,030220 oncology & carcinogenesis ,medicine ,General Earth and Planetary Sciences ,Radiology ,Differential diagnosis ,business ,18F-fluorocholine ,General Environmental Science - Abstract
Paget disease (PD) is a chronic disorder resulting in enlarged and misshapen bones, caused by disorganized bone remodeling. This case involves a 64-year-old man with prostatic adenocarcinoma and PD of some skeletal areas with increased uptake shown on 18 F-fluoro-methyl-choline (FMC) positron emission tomography/ computed tomography (PET/CT) performed for cancer restaging. Besides this feature, Paget disease may mimic metastases on PET/CT using various radiotracers, including 18 F-FMC PET/CT. In particular, this case highlights the potential of multiparametric disease characterization on PET. Therefore, in suspected cases, in which differential diagnosis is difficult, histology can be a helpful tool for diagnostic purposes.
- Published
- 2020
- Full Text
- View/download PDF
37. Will 18F-fluorocholine PET/CT replace other methods of preoperative parathyroid imaging?
- Author
-
Luca Giovanella, Arnoldo Piccardo, Lorenzo Bacigalupo, and Giorgio Treglia
- Subjects
PET-CT ,medicine.medical_specialty ,endocrine system diseases ,medicine.diagnostic_test ,business.industry ,Endocrinology, Diabetes and Metabolism ,Ultrasound ,030209 endocrinology & metabolism ,Imaging Procedures ,medicine.disease ,Scintigraphy ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Parathyroid imaging ,Positron emission tomography ,030220 oncology & carcinogenesis ,medicine ,Radiology ,business ,18F-fluorocholine ,Primary hyperparathyroidism - Abstract
Primary hyperparathyroidism (PHPT) is a common endocrine disorder usually due to hyperfunctioning parathyroid glands (HPs). Surgical removal of the HPs is the main treatment for PHPT, making the correct detection and localization of HPs crucial to guiding targeted and minimally invasive surgical treatment in patients with PHPT. To date, different imaging methods have been used to detect and localize HPs, including radiology, nuclear medicine, and hybrid techniques. The present work discusses the role and value of different imaging methods in PHPT and, particularly, evaluates the potential role of 18F-fluorcholine PET/CT as a “one-stop-shop” method for preoperative parathyroid localization in patients with PHPT. Cervical ultrasound (US) and parathyroid scintigraphy using 99mTc-MIBI are the most commonly employed methods in clinical practice. More recently, four-dimensional computed tomography (4D CT) and positron emission tomography (PET) with radiolabeled choline have emerged as useful alternatives in cases of negative or discordant findings from first-line imaging methods. Due to the excellent diagnostic performance of radiolabeled choline PET/CT and the low radiation burden, this technique seems to be an ideal candidate to substitute current imaging procedures including US, MIBI scintigraphy, 4D CT and MRI and perform a fast and reliable “one-stop-shop” preoperative localization of HP in patients with PHPT, including challenging cases of postoperative persistent/recurrent disease.
- Published
- 2020
- Full Text
- View/download PDF
38. Low-Grade Versus High-Grade Glioma… That Is the Question. 18F-Fluorocholine PET in the Detection of Anaplastic Focus
- Author
-
Carlos López Menéndez, Ana María García Vicente, José María Borrás Moreno, José Manuel Cordero García, and Ángel Soriano Castrejón
- Subjects
medicine.medical_specialty ,Focus (geometry) ,Choline ,030218 nuclear medicine & medical imaging ,Neovascularization ,03 medical and health sciences ,0302 clinical medicine ,Glioma ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,High-Grade Glioma ,Neoplasm Grading ,Neovascularization, Pathologic ,medicine.diagnostic_test ,Brain Neoplasms ,business.industry ,Magnetic resonance imaging ,General Medicine ,medicine.disease ,Magnetic Resonance Imaging ,Positron emission tomography ,Positron-Emission Tomography ,030220 oncology & carcinogenesis ,Radiology ,medicine.symptom ,business ,18F-fluorocholine - Abstract
Gliomas are characterized by intratumoral histological heterogeneity, coexisting foci of low and high grade. First, in low-grade gliomas, neoangiogenesis has not yet developed and cellularity is low, so alterations on perfusion MRI may not be present. Second, a non-negligible number of high-grade gliomas show none, patchy, or weak contrast enhancement on MRI, so they can be misdiagnosed as low-grade glioma, preventing their correct management. We present 4 cases of patients in which F-fluorocholine PET defined the anaplastic tumor component and therefore the tumor aggressiveness, solving the limitations of MRI.
- Published
- 2020
- Full Text
- View/download PDF
39. Head-to-head comparison of [18F]-fluorodeoxyglucose and [18F]-fluorocholine positron emission tomography/computed tomography in three patients with rare gestational trophoblastic neoplasms: A case series
- Author
-
Tossaporn Siriprapa, Tanyaluck Thientunyakit, Juri G. Gelovani, and Thonnapong Thongpraparn
- Subjects
Fluorodeoxyglucose ,lcsh:Medical physics. Medical radiology. Nuclear medicine ,[18f]-fluorocholine ,medicine.diagnostic_test ,business.industry ,[18F]-2’-fluoro-2’-deoxy-D-glucose ,lcsh:R895-920 ,Choriocarcinoma ,Standardized uptake value ,Case Report ,positron emission tomography/computed tomography ,medicine.disease ,Lesion ,[18f]-2'-fluoro-2'-deoxy-d-glucose ,Positron emission tomography ,choriocarcinoma ,gestational trophoblastic neoplasia ,Biomarker (medicine) ,Medicine ,medicine.symptom ,Nuclear medicine ,business ,18F-fluorocholine ,Positron Emission Tomography-Computed Tomography ,medicine.drug - Abstract
We report the efficacy of dual positron emission tomography/computed tomography (PET/CT) imaging with [18F]-2'-fluoro-2'-deoxy-D-glucose ([18F]-FDG) and [18F]-fluorocholine ([18F]-FCH) in patients with gestational trophoblastic neoplasia (GTN) for primary diagnosis and staging of this rare pregnancy-related disorder. Whole-body PET/CT with [18F]-FDG and [18F]-FCH was performed in three patients with GTN in 2 consecutive days. Each detectable lesion was characterized by visual and quantitative analyses. As compared to CT alone, PET/CT with [18F]-FDG and [18F]-FCH PET/CT revealed more hypermetabolic metastatic lesions in the body, but not in the brain. The standard uptake value of [18F]-FDG was generally higher than [18F]-FCH in all detectable tumor lesions. In conclusion, both [18F]-FDG and [18F]-FCH PET/CT can be used for diagnosis and staging for GTN, based on their sensitivity for small extracerebral metastatic lesions. Additional studies are warranted to determine whether the PET/CT imaging with [18F]-FDG and [18F]-FCH can serve as a biomarker of GTN aggressiveness, for prediction of treatment response.
- Published
- 2020
40. The utility of 18F-fluorocholine PET/CT in the imaging of parathyroid adenomas
- Author
-
Piszczek Stanislaw, Saracyn Marek, Gizewska Agnieszka, Mazurek Andrzej, Dziuk Miroslaw, Chudzinski Witold, and Witkowska-Patena Ewa
- Subjects
Technetium Tc 99m Sestamibi ,PET-CT ,business.industry ,Endocrinology, Diabetes and Metabolism ,Hyperparathyroidism, Primary ,Choline ,Parathyroid Glands ,Parathyroid Neoplasms ,Endocrinology ,Positron Emission Tomography Computed Tomography ,Humans ,Nuclear medicine ,business ,18F-fluorocholine - Abstract
Aim: to estimate sensitivity of 18F-FCH PET/CT in preoperative localisation of hyperfunctioning parathyroid glands in patients with primary hyperparathyroidism (PHPT). Methods: 65 consecutive patients with PHPT who underwent neck ultrasound (US) and 99mTc/99mTc-MIBI dual-phase parathyroid scintigraphy were prospectively enrolled. Twenty-two patients had unsuccessful parathyroid surgery prior to the study. PET/CT scans were performed 65.0 ± 13.3 min after injection of 218.5 ± 31.9 MBq of 18F-fluorocholine (FCH). Three experienced nuclear medicine physicians assessed the detection rate of hyperfunctioning parathyroid tissue. Response to parathyroidectomy and clinical follow-up served as a reference test. Per-patient sensitivity and positive predictive value (PPV) were calculated for patients who underwent surgery.Results: 18F-FCH PET/CT was positive in 61 patients, and negative in four. US and parathyroid scintigraphy showed positive and negative results in 20 , 45 and 17, 48, respectively. US showed nodular goiter in 31 patients and chronic thyroiditis in 9 patients. Parathyroid surgery was performed in 43 (66%) patients. 18F-FCH PET/CT yielded sensitivity of 100% (95% CI [87.99-100]) and PPV of 85.7% (95% CI [70.77-94.06]). Similar values were observed in patients with chronic thyroiditis, nodular goiter, and patients after an unsuccessful parathyroid surgery. PET/CT identified hyperparathyroidism complications (kidney stones, osteoporotic bone fractures and brown tumours) in 11 patients.Conclusions: 18F-FCH PET/CT effectively detected hyperfunctioning parathyroid tissue and its complications. The method showed excellent sensitivity and positive predictive value, including patients with nodular goiter, chronic thyroiditis and prior unsuccessful parathyroidectomy. PET/CT performance was superior to neck ultrasound and parathyroid scintigraphy.
- Published
- 2022
- Full Text
- View/download PDF
41. Unenhanced whole-body MRI versus PET-CT for the detection of prostate cancer metastases after primary treatment.
- Author
-
BARCHETTI, F., STAGNITTI, A., MEGNA, V., ANSARI, N. AL, MARINI, A., MUSIO, D., MONTI, M. L., BARCHETTI, G., TOMBOLINI, V., CATALANO, C., and PANEBIANCO, V.
- Abstract
OBJECTIVE: The aim of this study was to evaluate the accuracy of unenhanced whole-body MRI, including whole-body Diffusion Weighted Imaging (DWI), used as a diagnostic modality to detect pathologic lymph nodes and skeletal metastases in patients with prostate cancer (PCa) undergoing restaging after primary treatment. PATIENTS AND METHODS: 152 male patients with biochemical recurrence after radical prostatectomy (RP) or external beam radiation therapy (EBRT) underwent MRI at a 1.5 Tesla magnet with whole spinal sagittal T2-weighted, sagittal T1- weighted, sagittal STIR images, axial T1 and T2- weighted and STIR images of the pelvis and whole-body. 18Fcholine-PET/CT exam was used as the reference standard. RESULTS: MRI protocol including whole-body combined T1-weighted+T2-weighted+STIR+DWI showed a sensitivity (Se) of 99%, a specificity (Spe) of 98%, a positive predictive value (PPV) of 98%, a negative predictive value (NPV) of 96%, an accuracy of 98% and an area under the receiver operating characteristic curve (AUC) of 0.971 for identification of bone metastatic lesion. The same protocol, displayed a Se of 98%, a Spe of 99%, a PPV of 97%, a NPV of 98%, an accuracy of 98 % and an AUC of 0.960 in the detection of pathologic lymph nodes. CONCLUSIONS: Unenhanced whole-body MRI, including whole-body-DWI, is an accurate and cost-effective diagnostic tool which is able to detect lymph node involvement and bone metastases in patients with biochemically recurrent PCa after RP or EBRT. Thanks to its lack of ionizing radiation, excellent soft tissue contrast, high spatial resolution, no need of contrast agent, high Se and Spe, it could play a role in the restaging procedure of such patients. [ABSTRACT FROM AUTHOR]
- Published
- 2016
42. Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer
- Author
-
Lépinoy, Alexis, Silva, Yannick E., Martin, Etienne, Bertaut, Aurélie, Quivrin, Magali, Aubignac, Léone, Cochet, Alexandre, and Créhange, Gilles
- Published
- 2019
- Full Text
- View/download PDF
43. Parathyroid gland detection in hyperparathyroidism with 18F-fluorocholine PET/CT
- Author
-
Broos, Wouter Adrianus Maria, Broos, Wouter Adrianus Maria, Broos, Wouter Adrianus Maria, and Broos, Wouter Adrianus Maria
- Abstract
Accurate preoperative localization of hyperfunctioning parathyroid glands is important in patients with hyperparathyroidism who are planned for parathyroidectomy, especially since minimally invasive surgical procedures are regularly used nowadays. An upcoming imaging technique to localize hyperfunctioning parathyroid glands is PET/CT with 18F-fluorocholine (18F-FCH). In this thesis, several both technical as well as clinical aspects of this relatively new imaging method were studied. The current scientific literature related to 18F-FCH PET/CT was reviewed, which showed favorable results for this technique. Different scan acquisition protocols such as dual-time-point scanning and dynamic scanning were studied, which contributed to further optimalization of acquisition protocols. Furthermore, the incidence and relevance of incidental findings on 18F-FCH PET/CT were studied, and in a retrospective cohort study it was concluded that 18F-FCH PET/CT is an excellent imaging technique to detect hyperfunctioning parathyroid glands, not only in case conventional imaging methods are inconclusive, but also as a first-line imaging modality.
- Published
- 2021
44. 18F-fluorocholine PET/CT is more sensitive than 11C-methionine PET/CT for the localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism.
- Author
-
Mathey, Céline, Keyzer, Caroline, Blocklet, Didier, Van Simaeys, Gaëtan, Trotta, Nicola, Lacroix, Simon, Corvilain, Bernard, Goldman, Serge, Moreno Reyes, Mario Rodrigo, Mathey, Céline, Keyzer, Caroline, Blocklet, Didier, Van Simaeys, Gaëtan, Trotta, Nicola, Lacroix, Simon, Corvilain, Bernard, Goldman, Serge, and Moreno Reyes, Mario Rodrigo
- Abstract
Purpose: Preoperative molecular imaging is paramount to direct surgery in primary hyperparathyroidism (pHTP). We investigate the diagnostic performance of 18F-fluorocholine (18F-FCH) PET/CT compared to 11C-methionine (11C-MET) PET/CT for the localization of hyperfunctioning parathyroid tissue in patients with pHTP and negative or inconclusive 99mTc-sestaMIBI SPECT (MIBI) findings. Materials and Methods: Fifty-eight patients with biochemical evidence of pHTP and negative or inconclusive MIBI were referred for pre-surgical detection and localization of hyperfunctioning parathyroid tissue by 11C-MET- and 18F-FCH-PET/CT. The PET/CT results were classified into 3 categories (positive, inconclusive or negative) based on the nodular aspect of tracer uptake and the visualisation of corresponding nodules on CT. The PET/CT results were correlated with the surgical and histopathological findings used as gold standard. Results: Fifty-three patients were included for analysis. 18F-FCH-PET/CT was positive in 39 patients (74%), inconclusive in 5 (9%) and negative in 9 (17%), compared to 25 (47%), 12 (23%) and 16 (30%) respectively for 11C-MET-PET/CT. 18F-FCH localized 11 additional foci (6 positive and 5 inconclusive) compared to 11C-MET. Twenty-six patients (sex F/M ratio16/10) underwent surgery with resection of 31 lesions (22 adenomas, 6 hyperplastic glands, 3 carcinomas) and 1 normal gland. At follow-up, twenty-one (81%) patients were considered cured after surgery, while 3 (12%) patients had persistence of hypercalcaemia. With inconclusive cases being considered as negative, 18F-FCH-PET/CT correctly localized 26 lesions in 24/26 (92%) patients compared to 16 lesions in 15/26 (58%) patients localized by 11C-MET-PET/CT. Per patient-based sensitivity and positive predictive value (PPV) were 96% and 96% for 18F-FCH and 60% and 94% for 11C-MET (p<0.0001). Per lesion-based sensitivity and PPV were respectively 84% and 90% for 18F-FCH vs. 52% and 94% for 11C-MET (p<0.0001). Conclusi, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2021
45. 18F-fluorocholine PET/CT is more sensitive than 11C-methionine PET/CT for the localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism
- Author
-
Simon Lacroix, Celine Mathey, Rodrigo Moreno-Reyes, Serge Goldman, Didier Blocklet, Caroline Keyzer, Gaetan Van Simaeys, Bernard Corvilain, and Nicola Trotta
- Subjects
PET-CT ,Hypercalcaemia ,business.industry ,PET/CT ,Primary hyperparathyroidism ,Parathyroid adenoma ,Gold standard (test) ,Hyperplasia ,Sciences bio-médicales et agricoles ,medicine.disease ,18F-fluorocholine ,Lesion ,PET ,11C -methionine ,medicine ,Radiology, Nuclear Medicine and imaging ,medicine.symptom ,business ,Nuclear medicine ,Endocrine ,Pathological - Abstract
Purpose: Preoperative molecular imaging is paramount to direct surgery in primary hyperparathyroidism (pHTP). We investigate the diagnostic performance of 18F-fluorocholine (18F-FCH) PET/CT compared to 11C-methionine (11C-MET) PET/CT for the localization of hyperfunctioning parathyroid tissue in patients with pHTP and negative or inconclusive 99mTc-sestaMIBI SPECT (MIBI) findings. Materials and Methods: Fifty-eight patients with biochemical evidence of pHTP and negative or inconclusive MIBI were referred for pre-surgical detection and localization of hyperfunctioning parathyroid tissue by 11C-MET- and 18F-FCH-PET/CT. The PET/CT results were classified into 3 categories (positive, inconclusive or negative) based on the nodular aspect of tracer uptake and the visualisation of corresponding nodules on CT. The PET/CT results were correlated with the surgical and histopathological findings used as gold standard. Results: Fifty-three patients were included for analysis. 18F-FCH-PET/CT was positive in 39 patients (74%), inconclusive in 5 (9%) and negative in 9 (17%), compared to 25 (47%), 12 (23%) and 16 (30%) respectively for 11C-MET-PET/CT. 18F-FCH localized 11 additional foci (6 positive and 5 inconclusive) compared to 11C-MET. Twenty-six patients (sex F/M ratio16/10) underwent surgery with resection of 31 lesions (22 adenomas, 6 hyperplastic glands, 3 carcinomas) and 1 normal gland. At follow-up, twenty-one (81%) patients were considered cured after surgery, while 3 (12%) patients had persistence of hypercalcaemia. With inconclusive cases being considered as negative, 18F-FCH-PET/CT correctly localized 26 lesions in 24/26 (92%) patients compared to 16 lesions in 15/26 (58%) patients localized by 11C-MET-PET/CT. Per patient-based sensitivity and positive predictive value (PPV) were 96% and 96% for 18F-FCH and 60% and 94% for 11C-MET (p, info:eu-repo/semantics/published
- Published
- 2021
46. 18F-fluorocholine uptake in Paget’s disease in two patients with prostate cancer
- Author
-
I. Carrió, Francisco Fuentes, M. Sizova, S. Abouzian, Ángela Fernández, and Diego Alfonso López-Mora
- Subjects
Paget s disease ,Oncology ,medicine.medical_specialty ,Prostate cancer ,business.industry ,Internal medicine ,General Engineering ,General Earth and Planetary Sciences ,Medicine ,business ,medicine.disease ,18F-fluorocholine ,General Environmental Science - Published
- 2022
- Full Text
- View/download PDF
47. 18F-PSMA-1007 and 18F-fluorocholine PET/CT in prostate cancer progression diagnostics. First comparative experience
- Author
-
N. A. Meshcheriakova, M. B. Dolgushin, A. I. Pronin, V. B. Matveev, A. A. Odzharova, and D. I. Nevzorov
- Subjects
Biochemical recurrence ,Urology ,medicine.medical_treatment ,Brachytherapy ,urologic and male genital diseases ,030218 nuclear medicine & medical imaging ,pet/ct ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,biochemical recurrence ,Medicine ,prostate-specific antigen ,Radiology, Nuclear Medicine and imaging ,PET-CT ,medicine.diagnostic_test ,business.industry ,Prostatectomy ,18f-psma-1007 ,medicine.disease ,prostate cancer ,Prostate-specific antigen ,Oncology ,Nephrology ,Bone lesion ,Positron emission tomography ,030220 oncology & carcinogenesis ,Surgery ,18f-fluorocholine ,Nuclear medicine ,business - Abstract
Background. Prostate cancer progression remains as a major problem among patients after their radical treatment. During last years a broad spectrum radiopharmaceuticals had developed to reveal the cause of biochemical recurrence.Objective: the comparison of 18F-fluorocholine and 18F-prostate-specific membrane antigen-1007 (18F-PSMA-1007) diagnostic abilities for the prostate cancer progression detection.Materials and methods. In this study had been included 18F-fluorocholine and 18F-PSMA-1007 PET/CT (positron emission tomography combined with computed tomography) scans of 9 patients after radical treatment with increased prostate-specific antigen (PSA) level (range 0.10–9.06 ng/ml).Results. 18F-PSMA-1007-PET/CT detected lesions in 7 (77.8 %) out of 9 patients, after radical prostatectomy and brachytherapy, in comparison with negative 18F-fluorocholine-PET/CT results in all cases.Conclusion. In this pilot study, 18F-PSMA-1007-PET/CT has showed high potential in pathological changes detection among patients with increased PSA level (minimum 0.10 ng/ml) and demonstrated the advantages in comparison with 18F-fluorocholine-PET/CT, especially in terms of revealing local recurrence and metastatic lymph nodes, as well as, in bone lesions early detection.
- Published
- 2019
48. 18Fluorocholine PET/CT scanning with arterial phase-enhanced CT is useful for persistent/recurrent primary hyperparathyroidism: first UK case series results
- Author
-
S Khan, Kevin M. Bradley, Greg Sadler, Fergus V. Gleeson, Radu Mihai, and Ioannis Christakis
- Subjects
Parathyroidectomy ,PET-CT ,medicine.medical_specialty ,Enhanced ct ,business.industry ,medicine.medical_treatment ,030209 endocrinology & metabolism ,General Medicine ,medicine.disease ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Endocrine Surgery ,Surgery ,Radiology ,business ,18F-fluorocholine ,Primary hyperparathyroidism ,Arterial phase ,Positron Emission Tomography-Computed Tomography - Abstract
Introduction Redo parathyroidectomy for persistent/recurrent primary hyperparathyroidism is associated with a higher risk of complications and should be planned only with convincing localisation. We assessed whether 18fluorocholine positron emission tomography/computed tomography could identify parathyroid adenoma(s) in patients with persistent/recurrent primary hyperparathyroidism and negative conventional scans. Materials and methods A departmental database was used to identify patients with failed localisation attempts (sestamibi single photon emission computed tomography/computed tomography and/or computed tomography/magnetic resonance imaging and/or selective parathyroid hormone sampling) after previous unsuccessful surgery for primary hyperparathyroidism. 18Fluorocholine positron emission tomography was performed in all patients and redo surgery offered to those with positive findings. Results 18Fluorocholine positron emission tomography incorporating arterial and portal phase enhanced computed tomography was performed in 12 patients with persistent/recurrent primary hyperparathyroidism (four men and eight women). Seven patients (58%) were cured after excision of adenomas located in ectopic positions (n = 3) or in anatomical position (n = 4). Five patients (42%) had persistent hypercalcaemia and repeat 18fluorocholine scan confirmed that the area highlighted on preoperative scans was excised. The arterial phase enhancement of the computed tomography was significantly different between cured and not-cured patients (P = 0.007). All seven cured patients had either a strong or weak enhancing pattern on computed tomography. Standardised uptake value at 60 minutes in patients with successful surgery (range 2.7–15.7, median 4.05) was higher than in patients with failed surgery (range 1.8–5.8, median 3.2) but was not statistically significant (P = 0.300). Discussion 18fluorocholine scanning can identify elusive parathyroid adenomas, including those that are ectopic, and is useful in the management of patients with persistent/recurrent primary hyperparathyroidism when first-line scans are negative. The grading of the arterial phase of computed tomography can help to differentiate between true adenomas and false positive targets (lymph nodes).
- Published
- 2019
- Full Text
- View/download PDF
49. Development of a thin layer chromatography method for plasma correction of [18F]fluorocholine metabolites in positron emission tomography quantification studies in humans
- Author
-
Ángel Ríos, Magdalena Oporto, Margalida Galmés, María Toscano, Marta Ortiz, S. Rubí, Marina Villar, Pedro Bibiloni, Jesús Molina, Fernando Vega, Manuel Valiente, José Luis Chinchilla, Cristina Peña, and Carlos Gonzalez
- Subjects
Cancer Research ,Chromatography ,Resolution (mass spectrometry) ,medicine.diagnostic_test ,Metabolite ,Plasma ,Pet imaging ,Thin-layer chromatography ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,chemistry ,Positron emission tomography ,030220 oncology & carcinogenesis ,medicine ,Molecular Medicine ,Choline ,Radiology, Nuclear Medicine and imaging ,18F-fluorocholine - Abstract
Introduction After its intravenous injection, [18F]fluorocholine is oxidized by choline-oxidase into its main plasma metabolite, [18F]fluorobetaine. If PET kinetic modeling quantification of [18F]fluorocholine uptake is intended, the plasma input time-activity-curve of the parent tracer must be obtained, i.e., the fraction of the total plasma radioactivity corresponding to the nonmetabolized [18F]fluorocholine at each time has to be known. Hence our aim was to develop an easy-routine Thin-Layer-Chromatography (TLC) method to separate and quantify the relative fractions of [18F]fluorocholine and [18F]fluorobetaine as a function of time during PET imaging in humans. Methods First, we tested several combinations of solvents systems and layers to select the one showing the best resolution on non-radioactive standards. Thereafter, [18F]fluorobetaine was obtained through chemical oxidation of an [18F]fluorocholine sample at diferent incubation times and we applied the selected TLC-system to aliquots of this oxidation solution, both in a saline and in human deproteinized plasma matrices. The plates were detected by a radio-TLC-scanner. This TLC-system was finally applied to arterial plasma samples from 9 patients with high-grade-glioma undergoing brain PET imaging and a parent fraction curve was obtained in each of them. Results A TLC-system based on Silica-Gel-60//MeOH-NH3 was selected from the choline/betaine non-radioactive standards assay. Radiochromatograms of [18F]fluorocholine oxidation solution yielded two separated and well-defined peaks, Rf = 0,03 ([18F]fluorocholine) and Rf = 0.78 (18F]fluorobetaine) consistent with those observed on non-radioactive standards. During the oxidation, the [18F]fluorocholine radioactivity peak decreased progressively at several incubation times, while the other peak ([18F]fluorobetaine) increased accordingly. The mean values of the parent fraction of [18F]fluorocholine of the 9 patients studied (mean+/-SD) were 94% ± 6%, 58% ± 15%, 43% ± 10%, 39% ± 6% and 37% ± 6% at 2.8 min, 5.8 min, 8.8 min, 11.7 min and 14.7 min post-injection, respectively. Conclusions We have developed a TLC-system, easy to perform in a standard radiopharmacy unit, that enables the metabolite correction of arterial input function of [18F]fluorocholine in patients undergoing PET oncologic quantitative imaging.
- Published
- 2019
- Full Text
- View/download PDF
50. Dual-Time-Point 18F-Fluorocholine PET/CT in Parathyroid Imaging
- Author
-
Friso M. van der Zant, Wouter A. M. Broos, Maurits Wondergem, and Remco J.J. Knol
- Subjects
Hyperparathyroidism ,PET-CT ,business.industry ,medicine.disease ,030218 nuclear medicine & medical imaging ,Lesion ,03 medical and health sciences ,0302 clinical medicine ,Parathyroid imaging ,030220 oncology & carcinogenesis ,medicine ,Image acquisition ,Radiology, Nuclear Medicine and imaging ,medicine.symptom ,Nuclear medicine ,business ,18F-fluorocholine ,Dual time point ,Parathyroid adenoma - Abstract
18F-fluorocholine (18F-FCH) PET/CT is a promising and increasingly used scan technique in the preoperative imaging of parathyroid adenoma. Several acquisition methods have been evaluated in the literature, but the optimal image acquisition time point after administration of the tracer is still under debate. Methods: Patients who had hyperparathyroidism, underwent dual-time-point 18F-FCH PET/CT (image acquisition, 5 min; 60 min after injection), and had histologically proven pathologic parathyroid glands were retrospectively included in the study. Early and late images were compared both visually and quantitatively. Results: Sixty-four patients were included, and a total of 71 parathyroid glands were surgically removed. Visually, there were no differences between early and late images of hyperfunctioning parathyroid glands in 44 patients (69%); in 13 patients (20%), visualization on early images was better; in 6 patients (9%), visualization of hyperfunctioning glands was best on late images; and in 1 patient (2%), the lesion was exclusively visualized on late images. For the total cohort, there was a significant decrease in 18F-FCH uptake in the glands on late versus early time points (P = 0.001), but there was a significant increase in the ratio of parathyroid uptake to thyroid uptake (P = 0.037). The group of patients with better visualization on early images showed a decrease over time in both parathyroid uptake and the ratio of parathyroid uptake to thyroid uptake, significant in comparison to those in both the group with better visualization at later time points and the group in which visualization was similar at both time points (P values of 0.000-0.018). There were no significant differences in 18F-FCH uptake and the ratio of parathyroid uptake to thyroid uptake between the latter 2 groups (P values of 0.200-0.709). Conclusion: In most patients (89%), hyperfunctioning parathyroid glands were adequately visualized on early imaging; however, in a subset of patients (11%), such glands were best visualized at later time points. Therefore, we recommend the acquisition of dual-time-point images in parathyroid imaging with 18F-FCH PET/CT or the creation of an opportunity to acquire additional late images after review of early images when findings are inconclusive.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.